期刊
FUTURE ONCOLOGY
卷 17, 期 8, 页码 943-954出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2020-1063
关键词
breakthrough cancer pain; palliative care; quality of life; radiation oncology; transmucosal fentanyl
类别
资金
- Angelini Pharma Espana, S.L.U.
The CAVIDIOR study in Spain evaluated the quality of life in patients with breakthrough cancer pain receiving palliative radiation therapy. The study found that with appropriate diagnosis and management in radiation oncology departments, breakthrough cancer pain can be significantly reduced, leading to improvements in quality of life, sleep quality, and caregiver burden.
Aim: The CAVIDIOR study evaluated quality of life (QoL) in patients with breakthrough cancer pain receiving palliative radiation therapy in radiation oncology departments (RODs) in Spain. Patients & methods: Prospective observational study at 11 Spanish RODs (July 2016-November 2017). QoL was assessed using Short Form Health Survey 12. Secondary end points were sleep quality, caregiver burden and patient/perception of improvement. Results: QoL improved according to the Short Form Health Survey 12 mental component. Sleep quality and caregivers' burden improved significantly. Conclusion: Breakthrough cancer pain is highly prevalent and can be substantially reduced with appropriate diagnosis and management in RODs. Along with the QoL questionnaire, sleep quality and caregiver burden provide a more comprehensive assessment of overall health status in patients receiving radiation therapy in RODs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据